Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elevation Oncology (ELEV)
NASDAQ:ELEV
Elevation Oncology (ELEV) Stock Price & Analysis
214 Followers
ELEV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $5.83
Previous Close$2.64
Volume147.80K
Average Volume (3M)835.89K
Market Cap
$146.98M
Enterprise Value$71.00M
Total Cash (Recent Filing)$104.05M
Total Debt (Recent Filing)$30.81M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 01, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding54,638,262
10 Day Avg. Volume493,366
30 Day Avg. Volume835,894
Standard Deviation0.77
R-Squared0.01
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)2.55
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.83
Forecast
1Y Price Target
$8.17Price Target Upside203.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Elevation Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment is ongoing in the 120-patient Phase 1 dose escalation and expansion study to evaluate the anti-Claudin 18.2 ADC EO-3021 in patients with advanced gastric, esophageal, and pancreatic cancers in the US and Japan.
Financial HealthElevation had cash and cash equivalents of $104.1M and raised an additional $14.5M in net proceeds through its at-the-market (ATM) facility, which is believed to be sufficient to fund operations through 2026.
Strategic PartnershipsSupply agreements with LLY and GSK to support these combinations are encouraging.
Bears Say
Clinical TrialsATG-022 FiH data had the lowest ORR seen to date in this class (20%), which is an important new low anchor for the class.
CompetitionASCO will feature two FiH clinical datasets from competing Claudin 18.2-directed ADCs, IBI343 and LM-302, which could help set expectations for EO-3021.
Financial PerformanceThe company reported no revenues, and a net loss of $0.23 per diluted share, compared to consensus estimate of no revenues and a net loss of $0.20 per diluted share.
---
Ownership Overview
21.58% Insiders
3.55% Mutual Funds
62.61% Other Institutional Investors
12.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELEV FAQ
What was Elevation Oncology’s price range in the past 12 months?
Elevation Oncology lowest stock price was $0.36 and its highest was $5.83 in the past 12 months.
What is Elevation Oncology’s market cap?
Currently, no data Available
When is Elevation Oncology’s upcoming earnings report date?
Elevation Oncology’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Elevation Oncology’s earnings last quarter?
Elevation Oncology released its earnings results on May 02, 2024. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.028.
Is Elevation Oncology overvalued?
According to Wall Street analysts Elevation Oncology’s price is currently Undervalued.
Does Elevation Oncology pay dividends?
Elevation Oncology does not currently pay dividends.
What is Elevation Oncology’s EPS estimate?
Elevation Oncology’s EPS estimate is -$0.22.
How many shares outstanding does Elevation Oncology have?
Elevation Oncology has 54,638,264 shares outstanding.
What happened to Elevation Oncology’s price movement after its last earnings report?
Elevation Oncology reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went down -4.5%.
Which hedge fund is a major shareholder of Elevation Oncology?
Among the largest hedge funds holding Elevation Oncology’s share is Farallon Capital Management, L.L.C.. It holds Elevation Oncology’s shares valued at 20M.
---
Elevation Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.17 (203.72% Upside)
$8.17 (203.72% Upside)
Blogger Sentiment
Bullish
ELEV Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 16.4%
Last 30 Days ▲ 21.4%
Last 30 Days ▲ 21.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.54%
12-Months-Change
Fundamentals
Return on Equity
-71.82%
Trailing 12-Months
Asset Growth
41.70%
Trailing 12-Months
Company Description
Elevation Oncology
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
---
ELEV Stock 12 Month Forecast
Average Price Target
$8.17
▲(203.72% Upside)
Technical Analysis
Best Analysts Covering ELEV
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+6.57%
reiterated a buy rating 3 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +6.57% per trade.
---